Print Page  |  Close Window

2016 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
08/23/16LabCorp’s Acquisition of Sequenom Clears Antitrust Review
BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 23, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom, Inc. (“Sequenom”) by LabCorp has expired. As previously announced, LabCorp and Savoy Acquisition Corp., its direct wholly owned subsidiary (“Purchaser”), commenced a tender off... 
Printer Friendly Version
08/09/16LabCorp Commences Cash Tender Offer for All Outstanding Shares of Sequenom, Inc.
BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 9, 2016-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Sequenom, Inc. (NASDAQ: SQNM) for $2.40 per share. The tender offer is being made by Savoy Acquisition Corp., a wholly owned subsidiary of LabCorp, pursuant to an offer to purchase, dated August 9, 2016. LabCorp and Sequenom previously announced... 
Printer Friendly Version
08/02/16LabCorp Announces the Availability of the CDC Zika MAC-ELISA Test
The CDC Zika MAC-ELISA Test Has Received FDA Emergency Use Authorization and Complements the RealStar® Zika Virus RT-PCR Kit U.S. BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 2, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced the nationwide availability of testing for Zika virus using the Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA) developed by the Ce... 
Printer Friendly Version
07/27/16LabCorp Announces Agreement to Acquire Sequenom
Acquisition Creates Market Leader in NIPT, Women’s Health and Reproductive Genetics LabCorp CEO: ‘This is exactly the kind of strategic acquisition that LabCorp seeks’ BURLINGTON, N.C. & SAN DIEGO--(BUSINESS WIRE)--Jul. 27, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), the world’s leading healthcare diagnostics company, and Sequenom, Inc. (NASDAQ:SQNM), a pioneer in non-invasive prenatal testing (N... 
Printer Friendly Version
07/27/16Laboratory Corporation of America® Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance
Q2 Net revenue of $2.4 billion, up 7% over last year Q2 Diluted EPS of $1.91; Q2 Adjusted EPS of $2.31, up 11% over last year 2016 Adjusted EPS guidance raised to $8.60 – $8.95, up 9% to 13% over 2015 BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 27, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced results for the quarter ended June 30, 2016. “Cont... 
Printer Friendly Version
07/01/16Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 1, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
06/27/16LabCorp Announces Launch of New Companion Diagnostic for Non-Small Cell Lung Cancer
The Roche cobas® EGFR Mutation Test v2 is the First Blood-Based Liquid Biopsy Test Approved by FDA for Clinical Use BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 27, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of a new application for the companion diagnostic associated with the use of Tarceva® for the treatment of certain patients with non-small cell lung cancer (NSCLC). The Roche... 
Printer Friendly Version
06/08/16LabCorp is Scheduled to Present at the 36th Annual William Blair Growth Stock Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 8, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 36th Annual William Blair Growth Stock Conference. LabCorp’s presentation is planned for Tuesday, June 14, 2016 at 3:50 PM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp... 
Printer Friendly Version
06/06/16LabCorp Announces the Availability of the RealStar® Zika Virus Test
altona Diagnostics’ RealStar® Zika Virus RT-PCR Kit U.S. Has Received FDA Emergency Use Authorization BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 6, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced the nationwide availability of testing for Zika virus using the RealStar® Zika Virus RT-PCR Kit U.S. from altona Diagnostics GmbH. The test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug... 
Printer Friendly Version
06/01/16One Year After Launch, BRCA Share™ Open Data Initiative Reveals New Findings on BRCA Gene Mutations Linked to Hereditary Breast and Ovarian Cancer Risk
Co-Founded by Quest Diagnostics and Inserm, with LabCorp as First Member, BRCA Share is now the Largest Open BRCA Datashare of Curated BRCA Variants Clinically Suitable for Patient Management MADISON, N.J., PARIS, France, BURLINGTON, N.C. – June 1, 2016 – BRCA Share, a public-private BRCA gene datashare initiative, today announced the public release of a large collection of new data on genetic variants in the BRCA1 and BRCA2 genes. Mutations of these genes raise the risk of breast, ovarian and... 
Printer Friendly Version
05/19/16New Complementary Diagnostic Test Available from LabCorp for Treatment of Bladder Cancer
VENTANA PD-L1 (SP142) Assay Identifies Metastatic Patients with Urothelial Cancer that May Benefit from Treatment with TECENTRIQ® (atezolizumab) BURLINGTON, N.C.--(BUSINESS WIRE)--May 19, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced the nationwide availability of the VENTANA PD-L1 (SP142) Assay as a complementary diagnostic for TECENTRIQ (atezolizumab), a new immunotherapy treatment for patien... 
Printer Friendly Version
05/09/16LabCorp Announces the Launch of the Epi proColon® Test for Colorectal Cancer Screening
First FDA-Approved Blood-Based Colorectal Cancer Test Offers Alternative for Patients Non-Compliant with Existing Screening Options BURLINGTON, N.C.--(BUSINESS WIRE)--May 9, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the launch of Epi proColon®, a blood-based test for colorectal cancer screening that was approved on April 13, 2016 for clinical use by the U.S. Food and Drug Administration (FDA). Epi... 
Printer Friendly Version
05/06/16LabCorp to Webcast Its Annual Meeting of Stockholders
BURLINGTON, N.C.--(BUSINESS WIRE)--May 6, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that its Annual Meeting of Stockholders will be webcast live beginning May 11, 2016 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com. An archived replay of the audio webcast will be available for one year. About LabCorp® Laboratory Corporation of America® Holdings, an S&... 
Printer Friendly Version
04/25/16Laboratory Corporation of America® Holdings Announces 2016 First Quarter Results and Raises 2016 Guidance
Q1 Net revenue of $2.3 billion, up 30% over last year Q1 Diluted EPS of $1.55; Q1 Adjusted EPS of $2.02, up 15% over last year 2016 Adjusted EPS guidance raised to $8.55 – $8.95, up 8% to 13% over 2015 BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 25, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced results for the quarter ended March 31, 2016. “We... 
Printer Friendly Version
04/11/16LabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization Services for Covance Drug Development
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 11, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Jonathan Zung, Ph.D., has been named group president, Clinical Development & Commercialization Services for Covance Drug Development, effective April 5, 2016. Zung joins LabCorp from UCB, where he was vice president and head of Global Clinical Sciences and Operations, with responsibility for clinical operations, ... 
Printer Friendly Version
04/04/16Conversion Right Triggered for Labcorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 4, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
03/21/16LabCorp Completes Acquisition of Assets of Pathology, Inc.
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 21, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) has completed the previously-announced acquisition of substantially all of the operating assets of Pathology, Inc. following the satisfaction of all closing conditions. The acquisition includes Pathology, Inc.’s patient service centers used to conduct its medical testing and services business. “The added capabilities of Path... 
Printer Friendly Version
03/14/16Covance Announces Mobile Health Solutions to Support Use of Mobile Technology in Clinical Trials
Regulatory Consulting and Validation Services Enable Drug Development Innovation BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 14, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Covance Drug Development (Covance) has launched Mobile Health Solutions, a suite of new capabilities designed to help biopharmaceutical and technology companies navigate the rapidly evolving mobile health landscape. Covance’s Mob... 
Printer Friendly Version
03/11/16LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 11, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2016 to September 11, 2016, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
03/08/16LabCorp is Scheduled to Present at the Barclays Capital 2016 Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 8, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Barclays Capital 2016 Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 15, 2016 at 9:00 AM (ET). A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay. About LabC... 
Printer Friendly Version
03/02/16LabCorp is Scheduled to Present at the 37th Annual Raymond James Institutional Investors Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 2, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 37th Annual Raymond James Institutional Investors Conference. LabCorp’s presentation is scheduled for Wednesday, March 9, 2016 at 11:35 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. ... 
Printer Friendly Version
02/18/16Laboratory Corporation of America® Holdings Announces 2015 Fourth Quarter and Full Year Results and Provides 2016 Guidance
Record Q4 and 2015 Net Revenue of $2.2 billion and $8.5 billion, respectively Q4 and 2015 Diluted EPS of $1.11 and $4.34, respectively Record Q4 and 2015 Adjusted EPS of $1.98 and $7.91, respectively Q4 and 2015 Free Cash Flow of $300 million and $727 million, respectively 2016 Adjusted EPS guidance of $8.45 to $8.85, up 7% to 12% over 2015 2016 Free Cash... 
Printer Friendly Version
01/27/16LabCorp and Cheeriodicals Spread Cheer to UNC Children’s
CHAPEL HILL & BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 27, 2016-- A team from Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), along with Cheeriodicals, delivered cheer in the form of 160 big green boxes to patients at N.C. Children’s Hospital during a "Cheeriodicals Day" event held on Jan. 27. Cheeriodicals are "big green boxes of cheer" made up of, in this case, age-appropriate magazines and activity books, room decorations, puzzles, ... 
Printer Friendly Version
01/07/16LabCorp Announces New Board Member
Richelle Parham Named to the Board of Directors Effective February 8, 2016 BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 7, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Richelle Parham has been appointed to its Board of Directors, effective February 8, 2016. “We are delighted that Richelle has accepted our invitation to join the LabCorp Board of Directors,” said David P. King, chairman and chie... 
Printer Friendly Version
01/06/16LabCorp is Scheduled to Present at the 34th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 6, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 34th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Wednesday, January 13, 2016 at 11:00 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About Lab... 
Printer Friendly Version
01/04/16Proprietary LabCorp Clinical Decision Support Report Improves Adherence to Chronic Kidney Disease Treatment Guidelines
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the results of a recently published clinical research study that demonstrates improved physician adherence to chronic kidney disease (CKD) treatment guidelines through the use of LabCorp’s innovative clinical decision support (CDS) report. Treatment guidelines provide evidence-based information to help physicians and ... 
Printer Friendly Version
01/04/16Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version